Polycipro D Eye Drops
Polycipro D Eye Drops
Composition: Ciprofloxacin 0.3% w/v + Dexamethasone 0.1% w/v
Formulation: Eye Drops
Category: Antibiotic + Corticosteroid
Packaging: 10ML
Eye Care Focus
Trusted Eye Solutions
Quality Eye Products
Polycipro D Eye Drops
Description
Therapy/Class: Antibiotic + Corticosteroid
Mechanism of Action:
Ofloxacin: A fluorinated carboxyquinolone exerting potent bactericidal activity by selectively inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. This action arrests DNA replication, transcription, and repair in a broad spectrum of Gram-positive and Gram-negative ocular pathogens.
Dexamethasone: A highly efficacious, long-acting synthetic glucocorticoid that rapidly permeates the corneal epithelium to suppress cellular exudation, capillary permeability, and fibroblastic proliferation. It achieves potent suppression of the immune response by inhibiting the transcription of pro-inflammatory genes.
Ciprofloxacin: A second-generation fluoroquinolone providing rapid, concentration-dependent bactericidal activity by interrupting DNA gyrase, highly effective for acute bacterial keratitis.
Indications
Treatment of bacterial conjunctivitis caused by susceptible organisms
Superficial ocular bacterial infections as advised by the treating ophthalmologist
Note: This is an indicative Indication, please follow the doctors advise. Do not self medicate.
Dosage & Administration
Instill 1 drop into the inferior conjunctival cul-de-sac of the affected eye(s) as prescribed by the physician. Dosing frequency should be adjusted according to clinical response and severity.
Note: This is an indicative dosage, please follow the doctors advise. Do not self medicate.
References
1. O’Brien TP, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Arch Ophthalmol. 1995;113(10):1257-1265.
2. Osato MS, et al. Clinical applications of ofloxacin in ophthalmology. Am J Ophthalmol. 1989;108(4):514-515.
1. Notivol R, et al. Efficacy and safety of dexamethasone in ophthalmic suspensions. Am J Ophthalmol. 2004;137(4):780-781.
Warning: This information is only for the use of registered medical practitioners only.
